2型糖尿病合并大血管并发症的血清脂蛋白(a)水平改变

• 作 者: 胡茂清 杨溢 张执玉 邓尚平 张梅
• 机 构: 四川省糖尿病防治中心
• 出 处: 四川省卫生管理干部学院学报
• 发表日期: 1998年04期
• 关键词: 大血管并发症 糖尿病肾病 糖尿病组 血清脂蛋白 微血管病 酶联免疫吸附法 脂蛋白代谢 无显著性差异 心脑血管疾病 高胰岛素血症

目的：了解２型糖尿病合并大血管并发症时的Ｌｐ（ａ）水平改变。方法：采用酶联免疫吸附法对正常人、２型糖尿病人以及２型糖尿病合并冠心病、大血管病变和微血管病变的Ｌｐ（ａ）水平进行了测定。结果：２型糖尿病组的Ｌｐ（ａ）水平明显高于正常对照组（Ｐ＜０００１）。２型糠尿病的组间分析显示：合并冠心病组的Ｌｐ（ａ）水平高于２型糖尿病组、大血管和微血管病变组（Ｐ＜００５）；大血管病变组的Ｌｐ（ａ）水平高于２型糖尿病组（Ｐ＜００５），但与微血管病变组间无显著性差异（Ｐ＞００５）；微血管病变组和２型糖尿病组间无显著性差异（Ｐ＞００５）。结论：Ｌｐ（ａ）水平在２型糖尿病时已明显升高，在糖尿病合并冠心病和大血管并发症时升高更加突出。

Objective: To understand the changes of Lp (a) levels in type 2 diabetic patients with macrovascular complications. Methods: The levels of Lp (a) in coronary heart disease, macroangiopathy and microangiopathy in type 2 diabetes mellitus and type 2 diabetes mellitus were measured by enzyme-linked immunosorbent assay. Results: The level of Lp (a) in type 2 diabetic patients was significantly higher than that in normal controls (P <0001). The results of inter-group analysis of type 2 diabetes mellitus showed that the Lp (a) level in patients with coronary heart disease was higher than that in type 2 diabetes mellitus, macrovascular disease and microvascular disease (P <005) ) Were significantly higher than those in type 2 diabetes mellitus (P <005), but there was no significant difference between them (P> 005). There was no significant difference between type 2 diabetes mellitus and type 2 diabetes mellitus (P> 0  05). Conclusion: The level of Lp (a) has been significantly increased in patients with type 2 diabetes mellitus, especially in diabetic patients with coronary heart disease and macrovascular complications.